Agilent expands molecule manufacturing capacity

By The Science Advisory Board staff writers

August 18, 2020 -- Agilent Technologies said that it's expanding its Frederick, CO-based production facility to more than double its current capacity for developing the short DNA and RNA molecules used to create nucleic acid-based therapeutics.

Adding the higher-volume manufacturing line will help Agilent meet expected growth in demand from pharmaceutical and biotech companies for these molecules, called oligos, according to the company. Oligos have the potential to be used to develop treatments for cancer, COVID-19, cardiovascular disease, rare and infectious diseases, and other conditions, Agilent said.

The company expects to begin shipping molecules manufactured on the new line by the end of 2022.

If you like this content, please share it with a colleague!

Related Reading

High-throughput analysis speeds downstream process development
Adding high-throughput analysis helped speed up downstream process development for drug candidates based on monoclonal antibodies, according to a case...

Agilent unveils new handheld raw material ID system
Agilent Technologies has launched Vaya Raman, a handheld raw material identity verification system for pharmaceutical manufacturers.

Agilent launches new microarrays for cytogenetic testing
Agilent Technologies has unveiled three new microarrays to support pre- and postnatal research by cytogenetic laboratories.

Agilent to fund biotherapy incubator in India
Agilent Technologies has announced a partnership with the Indian Institute of Technology Delhi to advance biotherapeutic research in the country.

Agilent unveils SureSelect DNA kit
Agilent Technologies has debuted SureSelect XT HS2, a DNA kit designed to help laboratories prepare DNA sequencing libraries for cancer and genetics research.